Treatment News : Truvada as PrEP Appears Not to Damage Kidneys

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » February 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


February 19, 2014

Truvada as PrEP Appears Not to Damage Kidneys

The use of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) leads to a very small challenge to kidney function that is reversible after stopping treatment, aidsmap reports. Publishing their findings in the journal AIDS, investigators of the iPREX study randomly assigned 2,499 HIV-negative men and transgender women who have sex with men to receive daily Truvada or a placebo, and then performed kidney function screens both during and after treatment that lasted on average for 81 weeks.

Those in the treatment arm of the study experienced a small but significant drop in creatinine clearance, an indicator of kidney function, compared with those who received a placebo: -2.4 milliliters per minute as opposed to -1.1 mL/min. The difference developed after four weeks of treatment and remained until the participants stopped taking Truvada, after which their creatinine clearance levels returned to normal.

The researchers acknowledge that their findings are limited both by the low adherence to Truvada among study participants, as well as by the relatively short course of treatment.

They state that this study supports the importance of ongoing monitoring of serum creatinine during use of Truvada as PrEP.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: PrEP, pre-exposure prophylaxis, aidsmap, iPREX, AIDS, HIV, Truvada, tenofovir, emtricitabine, creatinine clearance.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.